Keywords: Genzyme, USA, FDA, Consent decree, Sanofi-Aventis

Genzyme meets first milestones of FDA consent decree

Article | 25 November 2010

Print This

US biotech major Genzyme (NASDAQ: GENZ) said yesterday that it has ended fill/finish operations within its Allston, Massachusetts, plant ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in